Browsing by Author "Micev, M. (7003864533)"
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade(2015) ;Djuric-Stefanovic, A. (16021199600) ;Micev, M. (7003864533) ;Stojanovic-Rundic, S. (23037160700) ;Pesko, P. (7004246956)Saranovic, Dj (57190117313)Purpose To analyze value of the computed tomography (CT) perfusion imaging in response evaluation of the esophageal carcinoma to neoadjuvant chemoradiotherapy (nCRT) using the histopathology as reference standard. Methods Forty patients with the squamous cell esophageal carcinoma were re-evaluated after the nCRT by CT examination, which included low-dose CT perfusion study that was analyzed using the deconvolution-based CT perfusion software (Perfusion 3.0, GE). Histopathologic assessment of tumor regression grade (TRG) according to Mandard's criteria served as reference standard of response evaluation. Statistical analysis was performed using Spearman's rank correlation coefficient (rS) and Kruskal-Wallis's test. Results The perfusion CT parameter values, measured after the nCRT in the segment of the esophagus that had been affected by neoplasm prior to therapy, significantly correlated with the TRG: blood flow (BF) (rS = 0.851; p < 0.001), blood volume (BV) (rS = 0.732; p < 0.001) and mean transit time (MTT) (rS = -0.386; p = 0.014). Median values of BF and BV significantly differed among TRG 1-4 groups (p < 0.001), while maximal esophageal wall thickness did not (p = 0.102). Median BF and BV were gradually rose and MTT decreased as TRG increased, from 21.4 ml/min/100 g (BF), 1.6 ml/100 g (BV) and 8.6 s (MTT) in TRG 1 group, to 37.3 ml/min/100 g, 3.5 ml/100 g and 7.5 s in TRG 2 group, 81.4 ml/min/100 g, 4.1 ml/100 g and 3.8 s in TRG 3 group, and 121.1 ml/min/100 g, 4.9 ml/100 g and 3.7 s in TRG 4 group. In all 15 patients who achieved complete histopathologic regression (TRG 1), BF was <30.0 ml/min/100 g. Conclusions CT perfusion could improve the accuracy in response evaluation of the esophageal carcinoma to nCRT. © 2015 Elsevier Ireland Ltd. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Hepatobiliary and Pancreatic: Pancreatic VIPomas associated with multiple endocrine neoplasia type I(2012) ;Masulovic, D. (57215645003) ;Stevic, R. (24823286600) ;Knezevic, S. (55393857000) ;Micev, M. (7003864533) ;Saranovic, D.J. (57190117313) ;Filipovic, A. (55015822600) ;Knezevic, D.J. (23397393600) ;Ivanovic, A. (56803549500)Djuric-Stefanovic, A. (16021199600)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication Is there a correlation between molecular markers and response to neoadjuvant chemoradiotherapy in locally advanced squamous cell esophageal cancer?(2012) ;Arsenijevic, Tatjana (6508074168) ;Micev, M. (7003864533) ;Nikolic, V. (36980401100) ;Gavrilovic, D. (8849698200) ;Radulovic, S. (7005858810)Pesko, P. (7004246956)Purpose: To evaluate the expression of epidermal growth factor receptor (EGFR), p53, p21 and thymidylate synthase (TS) in a pretherapy biopsy specimen of locally advanced squamous cell esophageal cancer and correlate these markers with response to neoadjuvant chemoradiotherapy. Methods: Sixty-two patients with histopathologically proven locally advanced (T3 or greater) squamous cell esophageal cancer were enrolled. The expression of EGRF, p53, p21 and TS markers was assessed with immunohistochemistry. Semiquantitative assessment of expression of these markers was performed based on the percent of the stained cells. Radiotherapy (45-50.4 Gy) was delivered concomitantly with 5-fluorouracil (5-FU)/leucovorin (LV)/cisplatin (CIS) chemotherapy. Five to 6 weeks after chemoradiation, response to treatment was assessed. Medically fit and operable patients were operated. The resected material under went histopathological evaluation of tumor expansion, histological classification after initial multimodality treatment (yp TNM), residual status and tumor regression grade (TRG). Results: Out of 62 patients enrolled, 41 (66%) were evaluated for molecular markers. Clinical response rate was 43.9%. Out of 41 patients, 12 (29%) underwent surgery. TRG 1 was noted in 58% of the patients. In a pretherapy tumor specimen, positive expression was noted in 80, 90, 80 and 71% for EGFR, p53, p21 and TS, respectively. We noted no statistically significant difference neither between tumor marker expression and clinical response to chemoradiation, nor between tumor marker expression and TRG. Conclusion: We registered no difference in response to treatment between EGFR, TS, p21 and p53 positive and negative staining. © 2012 Zerbinis Medical Publications. - Some of the metrics are blocked by yourconsent settings
Publication Is there a correlation between molecular markers and response to neoadjuvant chemoradiotherapy in locally advanced squamous cell esophageal cancer?(2012) ;Arsenijevic, Tatjana (6508074168) ;Micev, M. (7003864533) ;Nikolic, V. (36980401100) ;Gavrilovic, D. (8849698200) ;Radulovic, S. (7005858810)Pesko, P. (7004246956)Purpose: To evaluate the expression of epidermal growth factor receptor (EGFR), p53, p21 and thymidylate synthase (TS) in a pretherapy biopsy specimen of locally advanced squamous cell esophageal cancer and correlate these markers with response to neoadjuvant chemoradiotherapy. Methods: Sixty-two patients with histopathologically proven locally advanced (T3 or greater) squamous cell esophageal cancer were enrolled. The expression of EGRF, p53, p21 and TS markers was assessed with immunohistochemistry. Semiquantitative assessment of expression of these markers was performed based on the percent of the stained cells. Radiotherapy (45-50.4 Gy) was delivered concomitantly with 5-fluorouracil (5-FU)/leucovorin (LV)/cisplatin (CIS) chemotherapy. Five to 6 weeks after chemoradiation, response to treatment was assessed. Medically fit and operable patients were operated. The resected material under went histopathological evaluation of tumor expansion, histological classification after initial multimodality treatment (yp TNM), residual status and tumor regression grade (TRG). Results: Out of 62 patients enrolled, 41 (66%) were evaluated for molecular markers. Clinical response rate was 43.9%. Out of 41 patients, 12 (29%) underwent surgery. TRG 1 was noted in 58% of the patients. In a pretherapy tumor specimen, positive expression was noted in 80, 90, 80 and 71% for EGFR, p53, p21 and TS, respectively. We noted no statistically significant difference neither between tumor marker expression and clinical response to chemoradiation, nor between tumor marker expression and TRG. Conclusion: We registered no difference in response to treatment between EGFR, TS, p21 and p53 positive and negative staining. © 2012 Zerbinis Medical Publications. - Some of the metrics are blocked by yourconsent settings
Publication Micrometastasis of hypopharyngeal cancer(2014) ;Sabljak, P. (6505862530) ;Pesko, P. (7004246956) ;Stojakov, D. (6507735868) ;Micev, M. (7003864533) ;Keramatollah, E. (14071596700) ;Velickovic, D. (14072144000) ;Skrobic, O. (16234762800) ;Sljukic, V. (19934460700)Djikic-Rom, A. (56182303300)Purpose: The aim of this study is to estimate the incidence and clinical impact of lymph node micrometastases in hypopharyngeal squamous cell cancer (HSCC). Materials and methods: In this retrospective study, we enrolled 58 patients who have undergone surgery for HSCC (between January 2004 and January 2011). Pharyngolaryngectomy and oesophagectomy with selective bilateral neck dissection was performed in all patients. Based on standard histological examination, 17 patients met N0 and 8 patients met N1 criteria and were further evaluated for the presence of micrometastases and isolated tumour cells (ITC). Following immunohistochemical analysis, the patients were grouped according to the presence of micrometastases and ITCs. Results: In the pN0 group, cytokeratin-positive cells were detected in five patients, and they were marked as N0/CK+. Among these five patients, two were found to harbour micrometastases and ITCs, whilst in three, only ITCs were found. Two patients (11.75 %) were upstaged to pN1. The patients marked as N0/CK+ had a statistically significant worse overall survival rates than pN0 patients with tissue samples read as negative for cytokeratin immunostaining (p=0.019, p<0.05). In the pN1 group, cytokeratin-positive cells were detected in two patients, with one patient showing micrometastases and ITC, and the other showing ITC only. One patient was upstaged to pN2. Conclusion: Patients with lymph node micrometastases and ITC had worse overall survival rates, which may indicate that more aggressive post-operative treatment regimens should be considered for these HSCC patients. © 2014 Springer-Verlag. - Some of the metrics are blocked by yourconsent settings
Publication The utility of 99mTc-EDDA/HYNIC-TOC scintigraphy for assessment of lung lesions in patients with neuroendocrine tumors(2010) ;Pavlovic, S. (57225355345) ;Artiko, V. (55887737000) ;Sobic-Saranovic, D. (57202567582) ;Damjanovic, S. (7003775804) ;Popovic, B. (36127992300) ;Jakovic, R. (6603414534) ;Petrasinovic, Z. (56057995200) ;Jaksic, E. (6507797044) ;Todorovic-Tirnanic, M. (12772684600) ;Saranovic, Dj. (57218389995) ;Micev, M. (7003864533) ;Novosel, S. (48662745400) ;Nikolic, N. (54942575800)Obradovic, V. (7003389726)Our aim was to assess clinical utility of 99mTc-EDDA/HYNIC-TOC scintigraphy for evaluation of lung lesions in patients with neuroendocrine tumors (NETs). Single photon emission computed tomography (SPECT) of the thorax and whole body scintigraphy were performed in 34 patients using 99mTc-EDDA/HYNIC-TOC. Visual assessment was complemented by semiquantitative evaluation based on tumor to non-tumor (T/NT) ratio. Clinical, laboratory, and histological findings served as the standard for comparison. Enhanced tracer uptake was observed on both SPECT and whole body scintigraphy in 29 of 34 patients (88% sensitivity). T/NT ratios were significantly higher on SPECT than whole body images (2.96±1.07 vs.1.70±0.43, p<0.01) and did not correlate with NET proliferation index Ki-67 (r= - 0.36, p=0.27). Conclusion: 99mTc-EDDA/ HYNIC-TOC scintigraphy is useful for evaluation of NET tissue in the lungs. SPECT provides better visualization of lung lesions than whole body scintigraphy. The intensity of tracer uptake, however, does not relate to the proliferation rate of NETs. 99mTc-EDDA/HYNIC-TOC scintigraphy may be helpful for selecting and monitoring treatment options, particularly when radiolabeled somatostatin analogue therapy becomes available.
